7 September 2020 - Precision medicines rely on companion diagnostics to identify patient subgroups eligible for receiving the pharmaceutical product.
Until recently, the Belgian public health payer, RIZIV-INAMI, assessed precision medicines and companion diagnostics separately for reimbursement decisions. As both components are considered co-dependent technologies, their assessment should be conducted jointly from a health technology assessment perspective. As of July 2019, a novel procedure was implemented accommodating for this joint assessment practice.
The aim of this research was to formulate recommendations to improve the assessment in the novel procedure.